Home - Products - Angiogenesis - Bcr-Abl - Vamotinib

Vamotinib

Vamotinib

Catalog No. M35738

Vamotinib (PF-114) is an orally active and specific tyrosine kinase inhibitor with antiproliferative and antitumour activity.Vamotinib inhibits the phosphorylation of BCR/ABL and BCR/ABL-T315I, which promotes apoptosis.

Size	Price / USD	Stock	Quantity
1 mL x 10 mM in DMSO	303	In Stock
5MG	258	In Stock
10MG	424	In Stock
25MG	756	In Stock
50MG	1014	In Stock
100MG	1386	In Stock
200MG	1841	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Group Booking Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Vamotinib
Brief Description
Description
Storage
Note

Research use only, not for human use.
Reference

1. Mian AA, et al. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia. 2015 May;29(5):1104-14.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

AG957

Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
CZC-8004

CZC-8004 (CZC8004, Dianilinopyrimidine-01) is a pan-specific kinase inhibitor that binds to a broad range of tyrosine kinases.
Dasatinib

A potent, orally bioavailable, dual Src/Abl kinase inhibitor.

Sign In Join Free